AN EFFECTIVE TOOL FOR MANAGEMENT OF PATIENTS AND CLINICAL TRIALS
Tìm thấy 10,000 tài liệu liên quan tới từ khóa "AN EFFECTIVE TOOL FOR MANAGEMENT OF PATIENTS AND CLINICAL TRIALS":
IMPLEMENTATION OF A NURSE-LED SELFMANAGEMENT SUPPORT INTERVENTION FOR PATIENTS WITH CANCER-RELATED PAIN: A CLUSTER RANDOMIZED PHASE-IV STUDY WITH A STEPPED WEDGE DESIGN (EVANTIPAIN)
Pain self-management support interventions were effective in controlled clinical trials and meta analyses. However, implementation of these complex interventions may not translate into identical effects.
Satisfaction and efficacy of epidural analgesia after surgery at the department of required services treatment in the national hospital of obstetrics and gynecology
The proportion of patients treated with other pain management measures was 64.7%. The incidence of patients with undesirable effects was 2.9%. The proportion of patients who agreed to use the epidural anesthesia, if indicated for another procedure, was 50%. It could be concluded that postoperative p[r]
Predicting combinative drug pairs towards realistic screening via integrating heterogeneous features
Drug Combination is one of the effective approaches for treating complex diseases. However, determining combinative drug pairs in clinical trials is still costly. Thus, computational approaches are used to identify potential drug pairs in advance.
IMPROVING THE ASSESSMENT OF QUALITY OF LIFE IN THE CLINICAL CARE OF MYELOMA PATIENTS: THE DEVELOPMENT AND VALIDATION OF THE MYELOMA PATIENT OUTCOME SCALE (MYPOS)
Multiple myeloma is an incurable cancer with a rising incidence globally. Less toxic treatments are increasingly available, so patients are living longer and treatment decisions are increasingly guided by QOL concerns. There is no QOL assessment tool designed specifically for use in the clinical car[r]
Systematic evaluation of the methodology of randomized controlled trials of anticoagulation in patients with cancer
Randomized controlled trials (RCTs) that are inappropriately designed or executed may provide biased findings and mislead clinical practice. In view of recent interest in the treatment and prevention of thrombotic complications in cancer patients we evaluated the characteristics, risk of bias and th[r]
Insight into bladder cancer care: Study protocol of a large nationwide prospective cohort study (BlaZIB)
Despite the embedding of bladder cancer management in European guidelines, large variation in clinical practice exists for applied diagnostics and treatments. This variation may affect patients’ outcomes including complications, disease recurrence, progression, survival, and health-related quality o[r]
HEPATOCELLULAR CARCINOMA TARGETED THERAPY AND MULTIDISCIPLINARY P40 PPSX
in patients with excellent performance status and well-preserved (Childs A) liver function. The efficacy and safety of sorafenib in patients with poorer performance status and more advanced hepatic dysfunction is yet to be established. Assessment of[r]
10 Đọc thêm
ANTIVIRAL AGENTS VACCINES AND IMMUNOTHERAPIES PART 9 PPTX
its potential effects in the newborn and immunocompromised patient can be devastating. Congenital CMV is the most com- mon intrauterine infection in the United States, and an esti- mated 8000 American infants develop neurologic or fatal complications each year because of
44 Đọc thêm
DEFERASIROX, A NOVEL ORAL IRON CHELATOR, SHOWS ANTIPROLIFERATIVE ACTIVITY AGAINST PANCREATIC CANCER IN VITRO AND IN VIVO
Iron is essential for cell replication, metabolism and growth. Because neoplastic cells have high iron requirements due to their rapid proliferation, iron depletion may be a novel therapeutic strategy for cancer. Deferasirox (DFX), a novel oral iron chelator, has been successful in clinical trials i[r]
Nebulised hypertonic saline (3 %) among children with mild to moderately severe bronchiolitis - a double blind randomized controlled trial
Nebulized 3 % HS is effective, safe and superior to normal saline for outpatient management of infants with mild to moderately severe viral bronchiolitis in improving Clinical Severity Scores, facilitating early Out-Patient Department discharge and preventing hospital re-visits and admissions in the[r]
PIK3CA mutation is a favorable prognostic factor in esophageal cancer: Molecular profile by next-generation sequencing using surgically resected formalin-fixed, paraffin-embedded tissue
Practical and reliable genotyping procedures with a considerable number of samples are required not only for risk-adapted therapeutic strategies, but also for stratifying patients into future clinical trials for moleculartargeting drugs.
THE RANDOMISED CLINICAL TRIAL AND THE HAZARD RATIO – MEDICAL RESEARCH’S EMPEROR’S NEW CLOTHES
As the enthusiasm for individualized treatment and targeted therapies continues to gain momentum, it seems timely to re-assess whether our current research tools are fit for purpose. Randomized Clinical Trials compare groups of patients, the Hazard Ratio is a ‘group summary statistic’, and modeling[r]
Adjuvant therapy after resection of colorectal liver metastases: The predictive value of the MSKCC clinical risk score in the era of modern chemotherapy
Despite introduction of effective chemotherapy protocols, it has remained uncertain, if patients with colorectal cancer (CRC) liver metastases should receive adjuvant therapy. Clinical or molecular predictors may help to select patients at high risk for disease recurrence and death who obtain a surv[r]
Murine double minute 2 predicts response of advanced esophageal squamous cell carcinoma to definitive chemoradiotherapy
Background
Definitive chemoradiotherapy (dCRT) has recently be- come one of the most effective therapies for esophageal squamous cell carcinoma (ESCC) [1]. The clinical out- comes with this treatment have been comparable with surgery alone [2]. We also reported that d[r]
CHARACTERIZING AND PROGNOSTICATING CHRONIC LYMPHOCYTIC LEUKEMIA IN THE ELDERLY: PROSPECTIVE EVALUATION ON 455 PATIENTS TREATED IN THE UNITED STATES
Median age at diagnosis of patients with chronic lymphocytic leukemia (CLL) is > 70 years. However, the majority of clinical trials do not reflect the demographics of CLL patients treated in the community. We examined treatment patterns, outcomes, and disease-related mortality in patients ≥ 75 years[r]
INTRATUMORAL HETEROGENEITY IN A MINORITY OF OVARIAN LOW-GRADE SEROUS CARCINOMAS
Ovarian low-grade serous carcinoma (LGSC) has fewer mutations than ovarian high-grade serous carcinoma (HGSC) and a less aggressive clinical course. However, an overwhelming majority of LGSC patients do not respond to conventional chemotherapy resulting in a poor long-term prognosis comparable to wo[r]
Perfecting the mechanism for interest rate control in Vietnam today
Interest rate is one of crucial tools for central banks to administer its monetary policy, and has thus far been employed in many countries as an effective economic tool. Particularly in the market economy, it has become a useful tool for the central bank to control inflation and stimulate economic[r]
LEVELS OF ACTIVE TYROSINE KINASE RECEPTOR DETERMINE THE TUMOR RESPONSE TO ZALYPSIS
Zalypsis® is a marine compound in phase II clinical trials for multiple myeloma, cervical and endometrial cancer, and Ewing’s sarcoma. However, the determinants of the response to Zalypsis are not well known. The identification of biomarkers for Zalypsis activity would also contribute to broaden the[r]
BIOPRO-RCMI-1505 TRIAL: MULTICENTER STUDY EVALUATING THE USE OF A BIODEGRADABLE BALLOON FOR THE TREATMENT OF INTERMEDIATE RISK PROSTATE CANCER BY INTENSITY MODULATED RADIOTHERAPY; STUDY
Prospective trials have demonstrated the advantage of dose-escalated radiotherapy for the biochemical and clinical control of intermediate risk prostate cancer. Dose escalation improves outcomes but increases risks of urinary and bowel toxicity.
The role of autophagy in kidney inflammatory injury via the NF-κB route induced by LPS
Acute kidney injury (AKI) is a systemic inflammatory response syndrome associated with poor clinical outcomes. No treatments effective for AKI are currently available. Thus, there is an urgent need of development of treatments effective for AKI. Autophagy, an intracellular proteolytic system, is ind[r]